LUND, Sweden, Feb. 12, 2019 /PRNewswire/ --
(Nasdaq Stockholm: IMMNOV), to strengthen IR and shareholder communication Immunovia today announced that Julie Silber has joined as Director of Investor Relations. Bringing over 18+ years of investor relations, strategic communications, counsel and executive financial leadership experience, Julie has served as a trusted advisor to small and medium size public companies as both an Investor Relations Officer and CFO. She has been instrumental in executing all facets of the IR function and leveraging her deep institutional investor knowledge and business consulting expertise. She is currently Senior IR Advisor at Wildeco in Stockholm.
Julie's unique experience combines a deep understanding of Best Practice Investor Relations, the needs of non-US listed companies that wish to gain access and/or expand their exposure to the North American capital markets and most recently, over the last 4 years, working with Life Sciences companies in the Nordics.
"We are excited to welcome an executive of Julie's caliber to help expand Immunovia's best-in-class Investor Relations program. Julie will be working closely with Immunovia's senior management on the exciting prospects of expanding reach and exposure throughout Europe, North American and beyond," commented Mats Grahn, CEO of Immunovia. "Immunovia's strategic communications plan and IR function needs to adapt to support the company's continued development and we look forward to Julie's contribution to helps us do that."
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood-based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. (Source: www.immunovia.com)
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.
For more information, please contact:
Director of Investor Relations
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
SOURCE Immunovia AB